Armin Steffen1, Ayse Kilic1, Inke R König2, Maria V Suurna3, Benedikt Hofauer4, Clemens Heiser4. 1. Department of Otorhinolaryngology, University of Lübeck, Lübeck, Germany. 2. Institute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany. 3. Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine, New York, New York, U.S.A. 4. Department of Otorhinolaryngology-Head and Neck Surgery, Technical University of Munich, Munich, Germany.
Abstract
OBJECTIVES/HYPOTHESIS: Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA). Previous data have demonstrated a correlation between the phenotype of tongue motion and therapy response. Closed loop hypoglossal nerve stimulation implant offers five different electrode configuration settings which may result in different tongue motion. STUDY DESIGN: Two-center, prospective consecutive trial in a university hospital setting. METHODS: Clinical outcomes of 35 patients were analyzed after at least 12 months of device use. Tongue motion was assessed at various electrode configuration settings. Correlation between the tongue motion and treatment response was evaluated. RESULTS: OSA severity was significantly reduced with the use of UAS therapy (P < .001). Changes in tongue motion patterns were frequently observed (58.8%) with different electrode configuration settings. Most of the patients alternated between right and bilateral protrusion (73.5%), which are considered to be the optimal phenotypes for selective UAS responses. Different voltage settings were required to achieve functional stimulation levels when changing between the electrode settings. CONCLUSIONS: UAS is highly effective for OSA treatment in selected patients with an apnea-hypopnea index between 15 and 65 events per hour and higher body mass index. Attention should be given to patients with shifting tongue movement in response to change of electrode configuration. The intraoperative cuff placement should be reassessed when tongue movement shifting is observed. LEVEL OF EVIDENCE: 4 Laryngoscope, 1970-1976, 2018.
OBJECTIVES/HYPOTHESIS: Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA). Previous data have demonstrated a correlation between the phenotype of tongue motion and therapy response. Closed loop hypoglossal nerve stimulation implant offers five different electrode configuration settings which may result in different tongue motion. STUDY DESIGN: Two-center, prospective consecutive trial in a university hospital setting. METHODS: Clinical outcomes of 35 patients were analyzed after at least 12 months of device use. Tongue motion was assessed at various electrode configuration settings. Correlation between the tongue motion and treatment response was evaluated. RESULTS: OSA severity was significantly reduced with the use of UAS therapy (P < .001). Changes in tongue motion patterns were frequently observed (58.8%) with different electrode configuration settings. Most of the patients alternated between right and bilateral protrusion (73.5%), which are considered to be the optimal phenotypes for selective UAS responses. Different voltage settings were required to achieve functional stimulation levels when changing between the electrode settings. CONCLUSIONS:UAS is highly effective for OSA treatment in selected patients with an apnea-hypopnea index between 15 and 65 events per hour and higher body mass index. Attention should be given to patients with shifting tongue movement in response to change of electrode configuration. The intraoperative cuff placement should be reassessed when tongue movement shifting is observed. LEVEL OF EVIDENCE: 4 Laryngoscope, 1970-1976, 2018.
Authors: Katrin Hasselbacher; B Hofauer; J T Maurer; C Heiser; A Steffen; J U Sommer Journal: Eur Arch Otorhinolaryngol Date: 2018-05-28 Impact factor: 2.503
Authors: Markus Wirth; Daniel Unterhuber; Franziska von Meyer; Benedikt Hofauer; Armin Ott; Guenther Edenharter; Danny J Eckert; Clemens Heiser Journal: J Clin Sleep Med Date: 2020-01-13 Impact factor: 4.062
Authors: David Kent; Jeffrey Stanley; R Nisha Aurora; Corinna G Levine; Daniel J Gottlieb; Matthew D Spann; Carlos A Torre; Katherine Green; Christopher G Harrod Journal: J Clin Sleep Med Date: 2021-12-01 Impact factor: 4.062